Hypometabolism as a therapeutic target in Alzheimer's disease
2008

Using Ketone Bodies to Treat Alzheimer's Disease

Sample size: 20 publication 10 minutes Evidence: moderate

Author Information

Author(s): Costantini Lauren C, Barr Linda J, Vogel Janet L, Henderson Samuel T

Primary Institution: Accera, Inc.

Hypothesis

Can AC-1202 improve cognitive function in Alzheimer's disease by elevating serum ketone levels?

Conclusion

AC-1202 has been shown to improve memory and cognition in patients with mild-to-moderate Alzheimer's disease.

Supporting Evidence

  • AC-1202 improved memory and cognition in patients with mild-to-moderate Alzheimer's disease.
  • Higher serum BHB levels correlated with better cognitive performance.
  • ApoE4-negative patients showed significant improvement compared to ApoE4-positive patients.

Takeaway

This study suggests that a special treatment can help people with Alzheimer's by giving their brains a different kind of fuel to work better.

Methodology

The study involved clinical trials where patients received AC-1202 and their cognitive performance was measured.

Potential Biases

Potential bias due to the authors being employees of the company that manufactures AC-1202.

Limitations

The study had a small sample size and some participants experienced gastrointestinal distress.

Participant Demographics

Participants had a mean age of 74.7 years and included individuals diagnosed with probable Alzheimer's disease or mild cognitive impairment.

Statistical Information

P-Value

0.012

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2202-9-S16

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication